Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Study ID
NCT03645824
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Patients receive up to 4 cycles of pacritinib before allo-SCT

Study Details

The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.

Key Dates

Start date
Jun 4, 2018
Status verified
Aug 2022
Primary completion
Jul 31, 2023
Completion
Feb 28, 2027

Study Design

Enrollment
61 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib treatment befor allo-SCT
    The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.

Primary Outcome Measure

Proportion of patients receiving allo-SCT, with failure within or at day 180 post-transplant. [ Time Frame: 2 years ]

Related Studies